Perioperative Systemic Therapy for Resectable Non-Small Cell Lung Cancer

Despite remarkable treatment advancements in patients with advanced non & ndash;small cell lung cancer (NSCLC), recurrence rates for those with resectable, early-stage disease remains high. Immune checkpoint inhibitors and targeted therapies are 2 promising treat-ment modalities that may improve survival outcomes for patients with resected NSCLC when moved from the advanced stage to the curable setting. There are many clinical studies that have evaluated or are currently evaluating immunotherapy or targeted therapy in the perioperative setting, and recent trials such as CheckMate 816, ADAURA, and IMpower010 have led to new approvals and demon-strated the promise of this approach. This review discusses recent and ongoing neoadjuvant and adjuvant systemic therapy trials in NSCLC, and where the field may be going in the near future. J Natl Compr Canc Netw 2022;20(8):953 & ndash;961 doi: 10.6004/jnccn.2022.7021

Automated summary

Despite advancements in treatment for advanced non-small cell lung cancer (NSCLC), recurrence rates remain high for patients with resectable early-stage disease. Immune checkpoint inhibitors and targeted therapies show promise for improving survival outcomes when used in the curative setting instead of advanced stage treatment.